PTH and osteogenesis imperfecta: Also, medications in OI clinical trials such as BPS804 (NCT01417091; clinicaltrials.gov) and Romosozumab (NCT04545554; clinicaltrials.gov) (neutralizing anti-sclerostin antibodies), Denosumab (NCT01799798; clinicaltrials.gov) (neutralizing anti-RANKL antibody) and a combination of teriparitide (parathyroid hormone analog) with zolendronic acid (NCT01679080; clinicaltrials.gov) were originally not designed specifically for OI-related fractures.